跳至主要内容
临床试验/NCT00630461
NCT00630461终止1 期

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

University of North Carolina, Chapel Hill2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2008年5月1日最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
4
试验地点
2
主要终点
Increased sputum neutrophils with no adverse events

研究概览

简要总结

Endotoxin is a component of outdoor air pollution, an air contaminant found in a number of different workplaces, and is even found in homes. The endotoxin used for this study is obtained from the National Institutes of Health, and is called "Clinical Center Reference Endotoxin", or CCRE. The purpose of this Phase 1 research study is to identify a dose of inhaled endotoxin that is safe (does not cause prolonged cough, shortness of breath or other problems), but causes changes in your sputum cell samples that the scientists can measure. Phase 1 research studies like this one are not intended to be a treatment, but are a scientific investigation. Eventually, with these types of studies we will be able to examine why some people are more sensitive to endotoxin. Scientists at other universities have found that while most people do not have a considerable lung response to endotoxin at doses as high as 60,000 EU (endotoxin units), a few respond to as little as a total dose of 4500 EU. Our study is designed to identify if using a dose of 20,000 EU causes changes in the lung cells but does not cause symptoms in our study subjects. In our previous studies in our lab, using an endotoxin from another source, we have used higher doses (15,000 EUs) in subjects with asthma with no major problems, and we have used 10,000 EUs of CCRE in subjects with allergies and asthma without problems. We have used 20,000 EUs of CCRE in healthy individuals with no major problems.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Mild allergic rhinitis
  • Mild allergic asthma
  • Normal lung function
  • No other chronic illness

排除标准

  • Use of inhaled or oral steroids
  • Emergency treatment of asthma in last year
  • Inhaled tobacco use

结局指标

主要结局

Increased sputum neutrophils with no adverse events

时间窗: 6 hours post challenge

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David B. Peden, MD

Professor of Pediatrics

University of North Carolina, Chapel Hill

研究点 (2)

Loading locations...

相似试验